Navigation Links
Latest Study on Diabetes Drug Avandia Finds No Heart Risks
Date:6/29/2010

By Amanda Gardner
HealthDay Reporter

TUESDAY, June 29 (HealthDay News) -- In direct contrast to research reported on Monday, a new study concludes there is no increased risk of heart attack, stroke or death by taking the diabetes drug Avandia.

This latest finding even suggests that rosiglitazone (Avandia) might be associated with a slightly lower risk of heart attack, stroke or death in certain settings, compared to people not taking either Avandia or pioglitazone (Actos), the other drug in a class of diabetes medications known as thiazolidinediones (TZDs).

"Our observational study does not suggest a significant cardiovascular hazard and may suggest a beneficial effect on ischemic cardiovascular events associated with treatment with rosiglitazone among patients with type 2 diabetes and established coronary artery disease," said Dr. Richard Bach, an associate professor of medicine at Washington University School of Medicine in St. Louis.

Bach presented the findings at a news conference late Monday afternoon, during the American Diabetes Association (ADA) annual meeting in Orlando, Fla.

But on Monday morning, two other major studies came out with findings showing that Avandia increased the risk of cardiovascular trouble when compared to both a placebo and to Actos. Those studies appeared in the Journal of the American Medical Association and the Archives of Internal Medicine.

All of these findings will no doubt be hotly debated at a July meeting of U.S. Food and Drug Administration advisory panels that will recommend whether Avandia -- which has already weathered years of controversy -- should stay on the market.

In 2007, the FDA slapped a warning on Avandia's label after a meta-analysis showed that users faced an increased risk of heart attack and death from cardiovascular problems.

Although this latest study is much smaller than those presented Monday morning, the findings are not to be dismissed, said Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City.

"The FDA will look at this and when they put this together [with the other studies] they will come up with a warning -- be thoughtful about how to prescribe this -- but they will not take it off the market," Garratt predicted.

The study released Monday afternoon was from the Rosiglitazone and Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D) trial, originally designed not to look at the drug's safety but to determine how best to treat patients with both type 2 diabetes and coronary artery disease, a population at much higher risk of having a heart attack or stroke.

The study was funded by the U.S. National Institutes of Health as well as GlaxoSmithKline, which makes Avandia.

Almost 2,400 patients were randomly chosen to receive either medications plus angioplasty or bypass surgery, or medication alone.

Participants were also assigned to receive a drug to enhance insulin levels (including insulin itself) or drugs to help the body respond more effectively to insulin (either Avandia or metformin). The researchers noted that Avandia was not randomly prescribed but left to the discretion of individual physicians. That could detract from the validity of the findings, since randomized trials are considered the "gold standard" of research.

The researchers looked at 4.5 years of follow-up data. After adjusting for various factors, "the occurrence of death, heart attack and stroke was 28 percent less frequent" for those taking Avandia as compared with those patients not taking a TZD, said Bach.

The incidence of congestive heart failure was higher but this was not considered significant; there was a 45 percent increased risk of fractures, which was considered significant.

However, in one of the two studies published Monday -- a large review of data led by Dr. Steven Nissen of the Cleveland Clinic -- Avandia raised users' risk of heart attack by 28 percent to 39 percent.

So, how are doctors and patients to interpret such widely divergent views on the safety of Avandia?

One possibility is that "age is playing a role in a manner we don't even understand," Garratt said. The ages of the participants in the BARI 2D study were skewed downwards compared to the other research, where volunteers were older and therefore more likely to be more frail.

Avandia, along with its pharmacological cousin Actos, are different from many other diabetes drugs in that they act directly on gene expression.

"Because genes change over time, perhaps this type of drug is going to have different outcomes in different age groups," Garratt suggested.

"What we can conclude now looking at the question from multiple different angles is that we have failed to come up with a consistent message," Garratt added. "My guess is that the marketplace will see some additional fall-off in the use of Avandia, but we know that some has already taken place. Those of us who are prescribing the medication from a cardiovascular practice perspective are already cautious. As this gets more press, that degree of caution will filter down to the internist, the family medicine physician and the diabetes expert."

More information

The U.S. National Library of Medicine has more on thiazolidinediones.

SOURCES: Kirk Garratt, M.D., clinical director, interventional cardiovascular research, Lenox Hill Hospital, New York City; June 28, 2010, teleconference with: Richard Bach, M.D., associate professor, medicine, Washington University School of Medicine, St. Louis; American Diabetes Association annual meeting, Orlando. Fla.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Throwdown, a Leader in Impact and Action Sports, Debuts Latest Innovations at the Newest UFC Gym™ in Rosemead, California
2. Northridge Dentist, Dr. Ariz, Uses Latest Technological Advances to Give His Patients Faster, Painless Treatment
3. SNMs 2010 Annual Meeting reveals latest developments in molecular imaging and nuclear medicine
4. Caldwell Hospice Upgrades to Latest Version of CellTrak
5. Expert Insights on Health Data Sharing, Collaboration, Quality and Meaningful Use Featured in Latest Carefx Position Paper
6. A Rose in-Between Crown Thorns Morten Underbjerg Olesen's Latest Innovative Stencil Design
7. Book Delivers Latest ADHD Research, Treatments & Results
8. T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits
9. Business Customers in New England Receive the Latest Internet Telephone Service Upgrade
10. Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians
11. FlexRN Nurse Staffing Agency Prepares Nurses for Demands of Latest Health Care Reform
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Latest Study on Diabetes Drug Avandia Finds No Heart Risks
(Date:7/24/2017)... ... , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been appointed ... part of Saint Luke’s Health System . Dr. Upadhyaya has served in the ... FAANS joins Stanley P. Fisher, M.D., who has served as medical co-director ...
(Date:7/24/2017)... ... July 24, 2017 , ... A four alarm fire ... site and threatened numerous homes and businesses nearby, causing some 700 individuals to ... Los Angeles Area consulting firm Fire Protection Group, Inc. notes that the report ...
(Date:7/24/2017)... ... 24, 2017 , ... The Topricin Companies, formerly Topical Biomedics, ... revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. , ... skin conditions, including cancer. In the short term, overexposure to sun, wind ...
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... 24, 2017 , ... The Magic Wand® Rechargeable, the top-of-the-line ... favorite sex toy. Created in collaboration with website Kinkly.com, the award was the ... The Magic Wand Rechargeable won in stiff competition from brands such as Lelo, ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)... , July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, ... program to patients who suffer from painful intercourse and other painful pelvic ... vaginal atrophy due to menopause. ... VuVatech LLC ... created by Sarasota, Florida -based start-up company, VuVatech LLC, ...
Breaking Medicine Technology: